The drug prices of Diacomit, a treatment for Dravet syndrome, and Olpadine, a treatment for hereditary tyrosinemia, which is a rare essential drug, fell by up to 40%. The KOEDC said in a press release on the 1st, “In the case of Diacomit and Olpadine, insurance prices were voluntarily reduced on April 1 and May 1, respectively.” As a result, the price of Diacomit per capsule was reduced by about 23% from 19,160 won to 14,700 won. This is due to the fact that overseas wholesalers can reduce transportation costs by importing directly from the manufacturer, and as export certification by the manufacturer becomes possible, tariff exemption is possible under the Korea-EU FTA.

Olpadine cut the price by ab